Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Metrics: PDF 1586 views | ?
Present: The published funding information is incomplete.
Corrected: Additional funding information is given below.
This work was supported by Menarini Spain, grants PI 15/00598 from Fondo de Investigaciones Sanitarias (FIS) Carlos III Institute to A.A .; SAF2013-47611R from The Ministry of Economy and Competitiveness and grant S2010 / BMD-2321 (FIBROTEAM Consortium) from Autonomous Community of Madrid to M.L.-C .; G.L. Was Fully supported from theEuropean ETRiPD Marie Curie Project.
Original article: Oncotarget. 2015; 6:18875-90. DOI:10.18632/oncotarget.4303.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.